<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180011</url>
  </required_header>
  <id_info>
    <org_study_id>20041332</org_study_id>
    <nct_id>NCT00180011</nct_id>
  </id_info>
  <brief_title>Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma</brief_title>
  <official_title>Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiMango, Emily, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DiMango, Emily, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized, placebo controlled, double blind study to measure the safety
      and efficacy of a new, injectable asthma medication, omalizumab, in a group of minority with
      moderate to severe asthma who are not adequately controlled with use of inhaled or oral
      steroids. Primary endpont will be change in asthma symptom utility index. Secondary endpoints
      will be changes in asthma Quality of life, asthma exacerbation rate, and lung function over
      the 12 week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma symptom utility index</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints will be changes in asthma Quality of Life, asthma exacerbation rate, and lung function over the 12 week treatmet period.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>omaluzimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>injectable medication</description>
    <arm_group_label>omaluzimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-30

          -  Minority Patients

          -  Moderate or Severe allergic asthma (as defined by the National Asthma Education and
             Prevention Guidelines(7)]. Allergic asthma will be defined as elevated IgE level (&gt;
             100 IU/ml) and skin test sensitivity to at least one common aeroallergen

          -  asthma control score greater than 1.5 (5) at randomization visit with use of
             equivalent of at least 1000 mcg fluticasone daily or systemic steroid use

          -  FEV1 50-90% predicted at screening and randomization visit

        Exclusion Criteria:

          -  Active smoking within one year and/or greater than 10-pack year history of smoking

          -  Women of childbearing age must be using effective contraception

          -  Malignancy diagnosed within the past 5 years

          -  Underlying lung disease other than asthma

          -  Inability to comply with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily DiMango, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DiMango, Emily, M.D.</investigator_affiliation>
    <investigator_full_name>Emily DiMango</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>omalizumab</keyword>
  <keyword>severe asthma</keyword>
  <keyword>moderate asthma</keyword>
  <keyword>injectable asthma medication</keyword>
  <keyword>Xolair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

